September 6, 2017 – Cynvenio launches PD-L2 expression test. The first of its kind, the new blood test enables highly sensitive and specific profiling and monitoring of PD-L2 expression in cancer cells recovered from a simple blood draw.
August 31, 2017 – Paul Y. Song, M.D., Cynvenio Chief Medical Officer, will deliver a presentation, titled “The Role of Liquid Biopsies in Immunotherapy Selection and Monitoring” at the Select Biosciences Liquid Biopsies and Minimally-Invasive Diagnostics 2017 Conference in San Diego, California.
August 24, 2017 – Cynvenio announced the launch of its new ClearID HER2 Expression Test that allows doctors to perform real-time monitoring and analysis of HER2 levels in their patients without using tissue biopsy.
August 17, 2017 – Cynvenio Biosystems, Inc. announces the launch of a new breast cancer monitoring study in partnership with Saint Luke’s Cancer Institute in Kansas City, Missouri. The study’s goal is to evaluate the potential for early detection of recurrent breast cancer using LiquidBiopsy and natural killer (NK) cell testing in patients at high-risk of relapse after neoadjuvant chemotherapy.
August 8, 2017 - Cynvenio launches its second generation PD-L1 expression test. The new blood test offers improved analytic performance over the company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.
July 27, 2017 – Cynvenio announced that its LiquidBiopsy rare cell and cell-free isolation platform has been deployed at Severance Hospital of the Yonsei University Health System. Located in Gangnam-Gu, Seoul, Severance Hospital is one of the oldest and largest university hospitals in South Korea and has been treating patients continuously for 130 years.
June 4, 2017 — Download Cynvenio's poster from ASCO 2017 presenting preliminary data from the first year of our 211-patient TNBC clinical research study in a poster titled, “Use of serial multi-template liquid biopsies in triple negative breast cancer monitoring.”
June 1, 2017 – Cynvenio's LiquidBiopsy rare cell and cell-free isolation platform will be featured at the 2017 ASCO Annual Meeting at booth #23123. Also at the conference, study data collected via the LiquidBiopsy platform and supporting the utility of longitudinal monitoring of breast cancer patients will be published.
May 30, 2017 – Cynvenio to present preliminary data to support the utility of longitudinal monitoring of triple negative breast cancer patients using Cynvenio’s ClearID liquid biopsy tests at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois.
May 16, 2017 – Cynvenio announces the release of its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.
April 28, 2017 – Cynvenio in partnership with TME Research announced the launch of a new neoadjuvant breast cancer monitoring (NEAT) study. The multi-center registry study will include at least 10 centers and over 150 patients to be monitored over two years with Cynvenio’s ClearID Breast Cancer blood test.
April 3, 2017 – Cynvenio announces the immediate availability of two new antibody-based capture kits consisting of EGFR (epidermal growth factor receptor) and PSMA (prostate specific membrane antigen).